A process for the purification of 5-aminosalicylic acid (5-ASA) comprising the steps of: i) preparing an aqueous solution or suspension of 5-ASA, optionally added with at least another solvent; ii) adding a base until reaching a pH between 6 and 9; iii) adding an acid to the solution obtained from step ii) until reaching a pH between 3.2 and 5.2, preferably between 4.3 and 4.6, with consequent precipitation of 5-ASA; iv) separating the precipitated 5-ASA from step iii).
A manufacturing process to produce Linaclotide and its acetate salt, more particularly, to obtain amorphous High-Purity Linaclotide or its acetate salt with a chromatographic purity equal to or higher than 99.9% and a content of IMD-Linaclotide and Cys-1-α-ketone-Linaclotide impurities each one lower than 100 ppm, preferably lower than 50 ppm, more preferably lower than 40 ppm. The invention further relates to an analytical method able to detect IMD-Linaclotide and Cys-1-α-ketone Linaclotide even at 40 ppm level (LOD) and quantify IMD-Linaclotide and Cys-1-α-ketone Linaclotide even at 50 ppm level (LOQ), by Ion-Pairing Chromatography (IPC).
The object of tire present invention is a processfor the purification of 5-ASA. This process allows to obtain a product having a lower content of impurities and in an increased yield.
The object of the present invention is a process for the purification of 5-ASA. This process allows to obtain a product having a lower content of impurities and in an increased yield.
The present invention relates to a manufacturing process to produce Linaclotide and its acetate salt, more particularly, to obtain amorphous High-Purity Linaclotide or its acetate salt with a chromatographic purity equal to or higher than 99.9% and a content of IMD-Linaclotide and Cys-1-a-ketone-Linaclotide impurities each one lower than 100 ppm, preferably lower than 50 ppm, more preferably lower than 40 ppm. The invention further relates to an analytical method able to detect IMD-Linaclotide and Cys-1-a-ketone Linaclotide even at 40 ppm level (LOD) and quantify IMD- Linaclotide and Cys-1-o-ketone Linaclotide even at 50 ppm level (LOQ), by Ion- Pairing Chromatography (IPC).
The present invention relates to a manufacturing process to produce Linaclotide and its acetate salt, more particularly, to obtain amorphous High-Purity Linaclotide or its acetate salt with a chromatographic purity equal to or higher than 99.9% and a content of IMD-Linaclotide and Cys-1-a-ketone-Linaclotide impurities each one lower than 100 ppm, preferably lower than 50 ppm, more preferably lower than 40 ppm. The invention further relates to an analytical method able to detect IMD-Linaclotide and Cys-1-a-ketone Linaclotide even at 40 ppm level (LOD) and quantify IMD- Linaclotide and Cys-1-o-ketone Linaclotide even at 50 ppm level (LOQ), by Ion- Pairing Chromatography (IPC).
The object of the present invention is an anti-xylan sulfate antiserum having an antibody titre of between 1/10000 and 1/15000, and obtainable using a specific immunization method, and use thereof in one or more ELISA methods for determining xylan sulfate levels in biological fluids.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products, more precisely anticoagulant
products based on enoxaparin sodium used for the pre- and
postoperative prophylaxis of venous thromboembolic diseases,
associated to operations of general surgery, orthopaedic and
cancer surgery, prophylaxis and treatment of deep vein
thrombosis (DVT); anticoagulants.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, specifically anticoagulants based on enoxaparin sodium for use in pre and post-surgery prophylactic treatment of venous thromboembolic diseases, associated with general surgery, orthopaedic and cancer operations, prophylaxis and treatment of deep vein thrombosis (DVT); Anticoagulants.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, specifically anticoagulants based on enoxaparin sodium for use in pre and post-surgery prophylactic treatment of venous thromboembolic diseases, associated with general surgery, orthopaedic and cancer operations, prophylaxis and treatment of deep vein thrombosis (DVT); Anticoagulants.
11.
ANTI-XYLAN SULFATE POLYCLONAL ANTISERUM AND USE THEREOF IN ELISA METHODS
The object of the present invention is an anti-xylan sulfate antiserum having an antibody titre of between 1/10000 and 1/15000, and obtainable using a specific immunization method, and use thereof in one or more ELISA methods for determining xylan sulfate levels in biological fluids.
A method for the qualification and selection of manufacturing processes, raw materials, intermediates and batch production of pentosan polysulfate based on the identification of acetylated monosaccharide units, including units of xylose substituted with 4-O-methyl-glucuronic which also lead the acetyl group, as structural characterizing units, is disclosed.
C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
G01N 24/08 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
13.
ANTI-XYLAN SULFATE POLYCLONAL ANTISERUM AND USE THEREOF IN ELISA METHODS
The object of the present invention is an anti-xylan sulfate antiserum having an antibody titre of between 1/10000 and 1/15000, and obtainable using a specific immunization method, and use thereof in one or more ELISA methods for determining xylan sulfate levels in biological fluids.
A process for the purification of L-α-glycerophosphorylcholine is described, wherein L-α-glycerophosphorylcholine is crystallized from DMSO or from a mixture of DMSO with at least another solvent, preferably selected from water, alcohol, halogenated solvents, ethers, esters and/or amides. Such a process allows to obtain L-α-glycerophosphorylcholine having a purity greater than 99.5%, preferably greater than 99.7%, even more preferably greater than or equal to 99.9%. A method for determining the purity of L-α-glycerophosphorylcholine is also described, comprising the elution of L-α-glycerophosphorylcholine through an HPLC column having an amino stationary phase, and subsequent detection of L-α-glycerophosphorylcholine itself, and any impurity thereof, by means of an Evaporative Light Scattering Detector type.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products, more precisely anticoagulant
products based on enoxaparin sodium used for the pre- and
postoperative prophylaxis of venous thromboembolic diseases,
associated to operations of general surgery, orthopaedic and
cancer surgery, prophylaxis and treatment of deep vein
thrombosis (DVT); anticoagulants.
1 group on the same saccharide unit is defined as G, wherein G is hydrogen or acetyl, and wherein the sugar unit at the reducing end of sun such polysaccharide is xylose, lyxose or xylulose, said process comprising the following steps: selective deacetylation of xylan extracted from beech wood; and isomerization of the selectively deacetylated xylan achieved in step or the following steps: isomerization of xylan extracted from beech wood; and selective deacetylation of isomerized xylan achieved in step. The process is useful for the preparation of pentosan polysulfate or pharmaceutically acceptable salts thereof for pharmaceutical use.
The present invention relates to reversed phase high-performance liquid chromatography (HPLC) methods useful for the characterisation of glatiramer acetate or similar polypeptide mixtures. The method described herein can distinguish glatiramer acetate from non-conforming copolymers and may be used to choose batches of glatiramer acetate suitable for pharmaceutical use.
The present invention relates to simple size exclusion chromatography (SEC) analytical methods useful for the assessment of accurate molecular weight distributions (MWDs) of certain polypeptide mixtures known as glatiramoids. The use of a SEC method based on one or more broad MWD standards furnishes the absolute (not relative) molecular weight distribution profile of complex polypeptide mixtures like, for instance, the glatiramer acetate (GA) polymer.
The present invention relates to a process for the preparation of a polysaccharide composed of D-xylose units of formula (III) linked together via beta 1,4 glycosidic bonds wherein R1 is hydrogen or acetyl, R2 is hydrogen, acetyl or a 4-O-methyl glucuronic acid unit, wherein, when R2 is a 4-O-methyl glucuronic acid unit, the R1 group on the same saccharide unit is defined as G, wherein G is hydrogen or acetyl, and wherein the sugar unit at the reducing end of such polysaccharide is xylose, lyxose or xylulose, said process comprising the following steps: selective deacetylation of xylan extracted from beech wood; and isomerization of the selectively deacetylated xylan achieved in step or the following steps: isomerization of xylan extracted from beech wood; and selective deacetylation of isomerized xylan achieved in step. The process is useful for the preparation of pentosan polysulfate or pharmaceutically acceptable salts thereof for pharmaceutical use.
The present invention relates to a process for the preparation of a polysaccharide composed of D-xylose units of formula (III) linked together via beta 1,4 glycosidic bonds wherein R1 is hydrogen or acetyl, R2 is hydrogen, acetyl or a 4-O-methyl glucuronic acid unit, wherein, when R2 is a 4-O-methyl glucuronic acid unit, the R1 group on the same saccharide unit is defined as G, wherein G is hydrogen or acetyl, and wherein the sugar unit at the reducing end of such polysaccharide is xylose, lyxose or xylulose, said process comprising the following steps: selective deacetylation of xylan extracted from beech wood; and isomerization of the selectively deacetylated xylan achieved in step or the following steps: isomerization of xylan extracted from beech wood; and selective deacetylation of isomerized xylan achieved in step. The process is useful for the preparation of pentosan polysulfate or pharmaceutically acceptable salts thereof for pharmaceutical use.
A method for the qualification and selection of manufacturing processes, raw materials, intermediates and batch production of pentosan polysulfate based on the identification of acetylated monosaccharide units, including units of xylose substituted with 4-O-methyl-glucuronic which also lead the acetyl group, as structural characterizing units, is disclosed.
C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
G01N 24/08 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
22.
PROCESS FOR THE PURIFICATION OF L-.ALPHA.-GLYCEROPHOSPHORYLCHOLINE
A process for the purification of L-a-glycerophosphorylcholine is described, wherein L-a-glycerophosphorylcholine is crystallized from DMSO or from a mixture of DMSO with at least another solvent, preferably selected from water, alcohol, halogenated solvents, ethers, esters and/or amides. Such a process allows to obtain L-a-glycerophosphorylcholine having a purity greater than 99.5%, preferably greater than 99.7%, even more preferably greater than or equal to 99.9%. A method for determining the purity of L-a-glycerophosphorylchoiine is also described, comprising the elution of L-a-glycerophosphorylcholine through an HPLC column having an amino stationary phase, and subsequent detection of L- a-glycerophosphorylcholine itself, and any impurity thereof, by means of an Evaporative Light Scattering Detector type.
A process for the purification of L-α-glycerophosphorylcholine is described, wherein L-α-glycerophosphorylcholine is crystallized from DMSO or from a mixture of DMSO with at least another solvent, preferably selected from water, alcohol, halogenated solvents, ethers, esters and/or amides. Such a process allows to obtain L-α-glycerophosphorylcholine having a purity greater than 99.5%, preferably greater than 99.7%, even more preferably greater than or equal to 99.9%. A method for determining the purity of L-α-glycerophosphorylchoiine is also described, comprising the elution of L-α-glycerophosphorylcholine through an HPLC column having an amino stationary phase, and subsequent detection of L- α-glycerophosphorylcholine itself, and any impurity thereof, by means of an Evaporative Light Scattering Detector type.
The present invention relates to a new process for the synthesis of Colesevelam, which is used in therapy in cases of hypercholesterolemia due to low density lipoproteins. Said process comprises the reaction, in a basic environment, of polyallylamine with: i) at least one alkylating agent of formula X-(CH2)9-CH3 and at least one alkylating agent of formula Y-(CH2)6-N+ (CH3)3Z-, wherein X and Y are each independently a leaving group, and Z is a halogen; and ii) at least one crosslinking agent. The present invention also relates to the Colesevelam obtainable by the above process.
C08F 8/00 - Chemical modification by after-treatment
C08F 8/30 - Introducing nitrogen atoms or nitrogen-containing groups
C08F 8/44 - Preparation of metal salts or ammonium salts
C08F 226/02 - Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
An analytical method for the structural determination of polysaccharides, especially glycosaminoglycans (GAGs) such as heparin (RN=9005-49-6) is described which comprises the use of a mass spectrometer optionally coupled with a chromatographic or electrophoretic system. In a preferred embodiment, reverse phase ion pair HPLC is used to separate an enzyme digest of the polysaccharide and the fractions are analysed via ESI-QTOF mass spectrometry. In particular, a highly charged precursor ion (PI), which is resistant to S03 loss, is selected and subjected to collisional dissociation (CID), whereby the structure can be identified by the presence of characteristic fragment peaks at m/z 137.99, 138.97, 168.49, 157.01, 189.49... 369.10 etc. Applications include quality control of pharmaceutical products.
G01N 33/66 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood sugars, e.g. galactose
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
New formulations of bendamustine hydrochloride having HPLC purity higher than 99% obtained through the lyophilization of aqueous solutions without organic solvents, are described.
A method for the qualification and selection of manufacturing processes, raw materials, intermediates and batch production of pentosan polysulfate based on the identification of acetylated monosaccharide units, including units of xylose substituted with 4-O-methyl-glucuronic which also lead the acetyl group, as structural characterizing units, is disclosed.
Bortezomib esters with tartaric acid wherein the molar ratio between bortezomib and tartaric acid is 2:1 and formulations containing them are described.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products namely pharmaceutical preparations
for the treatment of neoplastic hyper-calcemia and for
prevention of events related to the skeletal system in
patients with malignant cancers at an advance stage
involving bone; pharmaceutical and veterinary preparations;
food for babies; plasters, materials for dressings; material
for stopping teeth and dental wax; disinfectants;
preparations for destroying vermin; fungicides, herbicides.
A process for the preparation of a prodrug of 5-aminosalicylic acid, namely 2-butanoyloxy-5-amino-benzoic acid,and solid forms of such compound are described.
C07C 227/04 - Formation of amino groups in compounds containing carboxyl groups
C07C 229/64 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by singly-bound oxygen atoms
31.
Polymorph of the hydrochloride of the (4-hydroxycarbamoyl-phenyl)-carbamic acid (6-dimethylamino methyl-2-naphthalenyl) ester
Herein described is a novel crystalline form of the hydrochloride of the (4-hydroxycarbamoyl-phenyl)-carbamic acid (6-dimethylamino methyl-2-naphtalenyl) ester. In particular, herein described is a polymorph of the hydrochloride of the (4-hydroxycarbamoyl-phenyl)-carbamic acid (6-dimethylamino methyl-2-naphtalenyl) ester, characterized by a Powder X Ray Diffraction spectrum as indicated in FIG. 1, and/or by a DSC profile as indicated in FIG. 2, and/or by a TGA profile as indicated in FIG. 3 and/or by an IR spectrum as indicated in FIG. 4.
A01N 37/00 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
A61K 31/21 - Esters, e.g. nitroglycerine, selenocyanates
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products; More precisely anti-thrombotic specialist pharmaceuticals for treating peripheral arteriopathy (including obliterant peripheral arteriopathy), treating chronic arterial ischemia and treatment of peripheral vascular diseases which are secondary to systemic diseases; Veterinary and sanitary preparations; Baby food; Plasters, materials for dressings; Material for stopping teeth and for dental impressions; Disinfectants; Preparations for destroying vermin; Fungicides; Herbicides.
Machines and machine tools, motors (except for land vehicles). Surgical and medical apparatus and instruments,In particular infusion pumps for administering medication.
34.
PROCESS FOR THE PREPARATION OF 2 -HYDROXY- 4 -PHENYL -3, 4 -DIHYDRO-2H-CHROMEN- 6 -YL -METHANOL AND (R) - FESO - DEACYL
The present invention regards an improved and industrially advantageous process for the preparation of the 2-hyaroxy-4-phenyl-3,4-dihydro-2H-chromen-6-yl-methanol intermediates, also called "feso chromenyl" and (R)-2-[3-(diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenol, also called "(R)-feso deacyl", which are in turn used in the synthesis of fesoterodine and in particular of fesoterodine furnarate. This process utilises reagents which are non-toxic and manageable at industrial level and enables obtaining a new stable and non-hygroscopic crystalline form of the key intermediate "(R)-feso deacyl", called form B.
C07D 311/20 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
C07C 215/54 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
C07C 219/28 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
35.
Process for the synthesis of azacitidine and decitabine
Described herein is a process for the synthesis of azacitidine or decitabine, comprising the silylation of azacytosine in the presence of N,O-bis-trimethylsilyl-trifluoroacetamide. Such reaction is performed in an organic solvent, preferably aprotic, even more preferably selected from among dichloromethane, dichloroethane and/or acetonitrile. According to a further aspect of the process, 2 to 3 moles of N,O-bis-trimethylsilyl-trifluoroacetamide are used per mole of azacytosine, preferably from 2.2 to 2.5.
C07H 1/00 - Processes for the preparation of sugar derivatives
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
36.
NOVEL POLYMORPH OF THE HYDROCHLORIDE OF THE (4-HYDROXYCARBAMOYL-PHENYL)-CARBAMIC ACID (6-DIMETHYLAMINO METHYL-2-NAPHTALENYL) ESTER
Herein described is a novel crystalline form of the hydrochloride of the (4- hydroxycarbamoyl-pheny3)-carbamic acid (6-dimethylamino methyl-2- naphtalenyl) ester. In particular, herein described is a polymorph of the hydrochloride of the (4- hydroxycarbamoyl-phenyl)-carbamic acid (6-dimethylamino methyl-2- naphtalenyl) ester, characterized by a Powder X Ray Diffraction spectrum as indicated in Figure 1, and/or by a DSC profile as indicated in figure 2, and/or by a TGA profile as indicated in figure 3 and/or by an IR spectrum as indicated in figure 4.
A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
C07C 269/08 - SeparationPurificationStabilisationUse of additives
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
37.
NOVEL POLYMORPH OF THE HYDROCHLORIDE OF THE (4-HYDROXYCARBAMOYL-PHENYL)-CARBAMIC ACID (6-DIETHYLAMINO METHYL-2-NAPHTHALENYL) ESTER
Herein described is a novel crystalline form of the hydrochloride of the (4-hydroxycarbamoyl-pheny3)-carbamic acid (6-diethylamino methyl-2- naphtalenyl) ester. In particular, herein described is a polymorph of the hydrochloride of the (4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylamino methyl-2- naphtalenyl) ester, characterized by a Powder X Ray Diffraction spectrum as indicated in Figure 1, and/or by a DSC profile as indicated in figure 2, and/or by a TGA profile as indicated in figure 3 and/or by an IR spectrum as indicated in figure 4.
A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
C07C 269/08 - SeparationPurificationStabilisationUse of additives
C07C 271/28 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
38.
Process for the production of N-acyl-phosphatidyl-ethanolamine
30, pure or mixed together, and X═OH or OM, where M=alkaline metal or alkaline earth, ammonium or alkylammonium. The process in question allows the conversion of lecithin of synthetic or natural origin into N-Acyl-Phosphatidyl-Ethanolamine of formula (I) of high purity, using a limited molar excess of the reagent N-acyl-ethanolamine, where the acyl is as defined above for the formula (I) through reaction of transphosphatidylation in the presence of the enzyme phospholipase D and in conditions suitable for production on an industrial scale.
Described is a new process for producing temozolomide, comprising the reaction between 5-aminoimidazole-4-carboxamide and N-succinimidyl-N′-methyl carbamate and the subsequent reaction of the thus obtained carbamoyl 5-aminoimidazole-4-carboxamide with sodium nitrite. Temozolomide is then purified by chromatography on adsorbent polymeric resin and subsequent crystallization from water and acetone.
C07D 233/66 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
40.
PROCESS FOR THE PRODUCTION OF N-ACYL-PHOSPHATIDYL-ETHANOLAMINE
The document describes a process for the preparation of N-Acyl-Phosphatidyl-Ethanolamine of formula (I) on an industrial scale, In which R1, R2 and R3 are, independently from each other, saturated, monounsaturated or polyunsaturated acyls C1O-C30, pure or mixed together, and X=OH or OM, where M= alkaline metal or alkaline earth, ammonium or alkylammonium. The process in question allows the conversion of lecithin of synthetic or natural origin into N-Acyl-Phosphatidyl-Ethanolamine of formula (I) of high purity, using a limited molar excess of the reagent N-acyl-ethanolamine, where the acyl is as defined above for the formula (I) through reaction of transphosphatidylation in the presence of the enzyme phospholipase D and in conditions suitable for production on an industrial scale.
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Produits pharmaceutiques, vétérinaires et hygiéniques;
substances diététiques à usage médical, aliments pour bébés;
emplâtres, matériel pour pansements; matières pour plomber
les dents et pour empreintes dentaires; désinfectants;
produits pour la destruction des animaux nuisibles;
fongicides, herbicides.
